Business

IIE DIGITAL DESK | June 22, 2026 : Shares of pharmaceutical major Cipla witnessed a sharp rally of nearly 4% in Monday’s trade after global brokerage firm Citi placed the stock on a 90-day Positive Catalyst Watch, sparking renewed investor optimism around the counter. The stock touched an intraday high of around ₹1,409 on the BSE, extending strong buying momentum throughout the session. 

The brokerage has maintained its “Buy” rating on Cipla while also retaining a target price of ₹1,700, indicating a potential upside of around 20–26% from current levels. The “Catalyst Watch” signals that Citi expects important near-term developments that could positively impact the company’s stock performance over the next quarter. 

Market sentiment turned bullish after the brokerage highlighted multiple expected triggers for Cipla’s growth trajectory, particularly in its US generics business. Key catalysts include the anticipated approval of gFlovent, the expected launch of gVentolin, and strengthening momentum in Nintedanib, where Cipla has been steadily expanding its market share. These developments are expected to support revenue visibility and margin improvement in the coming quarters. 

Analysts also pointed to improving prospects in Cipla’s domestic pharmaceutical business, especially the recovery in its respiratory portfolio, which remains a core growth driver for the company. In addition, regulatory developments such as the upcoming USFDA re-inspection of Cipla’s Indore facility are being closely tracked, with a favourable outcome seen as a potential positive trigger for the stock. 

Citi further noted that while Cipla is trading at relatively premium valuations compared to historical averages, the stock still appears attractive given its strong mix of domestic and international exposure and the expected revival in earnings growth over FY27–FY28. 

The brokerage upgrade, Cipla emerged as one of the top gainers in the Nifty 50 index, reflecting broad-based buying interest in pharma stocks amid supportive sectoral sentiment.

The sharp rise in Cipla shares highlights how brokerage-led optimism and upcoming business catalysts continue to play a key role in driving near-term momentum in the stock. Investors will now closely watch execution on US launches and regulatory outcomes to assess whether the bullish outlook translates into sustained gains.